One big task for Gilead Sciences’ HIV franchise in the coming year is to save some $2.5 billion in annual sales by switching as many PrEP patients as possible from Truvada to newly approved Descovy ...
Gilead Sciences, after striking a similar deal in 2014 to delay generics of its earlier HIV pre-exposure prophylaxis (PrEP) med Truvada, has followed suit on its key next-gen offering Descovy. Monday, ...
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for DESCOVY® (emtricitabine 200 mg and ...
A new HIV prevention option works well for gay and bisexual men and transgender women and should be approved by the Food and Drug Administration for these populations, according to an expert advisory ...
George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine (TDF/FTC) since ...
Truvada and Descovy are both manufactured by Gilead Sciences and used to treat HIV-1 infection and as pre-exposure prophylaxis (PrEP) in adult and pediatric patients. On July 1, 2019, the FDA removed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results